• Editor’s Pick
  • Investing
  • Economy
  • Stock
  • Politics
Income Researchers
Investing

5 Small-cap Biotech ETFs to Watch

by July 1, 2025
July 1, 2025

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, they give sector participants exposure to many biotech companies via one vehicle.

ETFs are a popular choice as they allow investors to enter the market more safely compared to investing in standalone stocks. A key advantage is that even if one company in the ETF takes a hit, the impact will be less direct.

All other figures were also current as of that date. Read on to learn more about these investment vehicles.

1. ALPS Medical Breakthroughs ETF (ARCA:SBIO)

AUM: US$81.2 million

Launched in December 2014, the ALPS Medical Breakthroughs ETF tracks small- and mid-cap biotech stocks that have one or more drugs in either Phase II or Phase III US FDA clinical trials. Its holdings must have a market cap between US$200 million and US$5 billion.

There are 104 holdings in this biotechnology fund, with about 50 percent being small- and micro-cap stocks. Its top holdings include Nuvalent (NASDAQ:NUVL) at a weight of 3.55 percent, Axsome Therapeutics (NASDAQ:AXSM) at 3.42 percent and Alkermes (NASDAQ:ALKS) at 3.18 percent.

2. Tema Oncology ETF (NASDAQ:CANC)

AUM: US$72.18 million

The Tema Oncology ETF provides exposure to biotech companies operating in the oncology industry. It includes companies developing a range of cancer treatments, including CAR-T cell therapies and bispecific antibodies.

Launched in August 2023, there are 51 holdings in this biotechnology fund, of which about half are small- to mid-cap stocks. Among its top holdings are Roche Holding (OTCQX:RHHBF,SWX:RO) at a weight of 5.32 percent, Eli Lilly and Company (NYSE:LLY) at 5.19 percent and BridgeBio Pharma (NASDAQ:BBIO) at 4.88 percent.

3. Direxion Daily S&P Biotech Bear 3x Shares (ARCA:LABD)

AUM: US$52.8 million

The Direxion Daily S&P Biotech Bear 3x Shares ETF is designed to provide three times the daily return of the inverse of the S&P Biotechnology Select Industry Index, meaning that the ETF rises in value when the index falls and falls in value when the index rises. Leveraged inverse ETFs are designed for short-term trading and are not suitable for holding long-term. They also carry a high degree of risk as they can be significantly affected by market volatility.

Unlike the other ETFs on this list, LABD achieves its investment objective through holding financial contracts such as futures rather than holding individual stocks.

4. Tema Heart and Health ETF (NASDAQ:HRTS)

AUM: US$50.83 million

Launched in November 2023, the Tema GLP-1 Obesity and Cardiometabolic ETF tracks biotech stocks with a focus on diabetes, obesity and cardiovascular diseases. The fund was renamed on March 25 from Tema Cardiovascular and Metabolic ETF, and again on June 27 from the GLP-1 Obesity and Cardiometabolic ETF.

There are 47 holdings in this biotechnology fund, with about 75 percent being large-cap stocks and 18 percent mid-cap. About three-quarters of its holdings are based in the US. Its top holdings are Eli Lilly and Company at a 9.78 percent weight, Abbott Laboratories (NYSE:ABT) at 4.58 percent and Novo Nordisk (NYSE:NVO) at 4.42 percent.

5. ProShares Ultra NASDAQ Biotechnology (NASDAQ:BIB)

AUM: US$47 million

The ProShares Ultra NASDAQ Biotechnology ETF was launched in April 2010 and is leveraged to offer twice daily long exposure to the broad-based NASDAQ Biotechnology Index, making it an ideal choice “for investors with a bullish short-term outlook for biotechnology or pharmaceutical companies.” However, analysts also advise investors with a low risk tolerance or a buy-and-hold strategy against investing in this fund due to its unique nature.

Of the 262 holdings in this ETF, the top biotech stocks are Gilead Sciences (NASDAQ:GILD) at a 5.57 percent weight, Vertex Pharmaceuticals (NASDAQ:VRTX) at 5.53 percent and Amgen (NASDAQ:AMGN) at 5.33 percent.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com
previous post
Mali Completes Takeover of Abandoned Gold Mines, Extends Push for Resource Sovereignty
next post
13 Uranium Companies Exploring Canada’s Athabasca Basin

Related Posts

13 Uranium Companies Exploring Canada’s Athabasca Basin

July 1, 2025

Mali Completes Takeover of Abandoned Gold Mines, Extends...

July 1, 2025

Ian Rodger Appointed Managing Director

July 1, 2025

South Harz Potash Limited

June 30, 2025

Equity Metals

June 30, 2025

Zijin Mining to Acquire Major Kazakh Gold Mine...

June 30, 2025

Terra Clean Energy: Advancing an Expansive Uranium Landholding...

June 30, 2025

Terra Clean Energy

June 30, 2025

Crypto Market Recap: Metaplanet Buys 1,005 Bitcoin, Plans...

June 30, 2025

Nuvau Announces Voting Results of Its Annual and...

June 30, 2025

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Trump warns of ‘whopping 68% tax increase’ if Senate fails to pass historic bill

      July 1, 2025
    • 13 Uranium Companies Exploring Canada’s Athabasca Basin

      July 1, 2025
    • 5 Small-cap Biotech ETFs to Watch

      July 1, 2025
    • Mali Completes Takeover of Abandoned Gold Mines, Extends Push for Resource Sovereignty

      July 1, 2025
    • Ian Rodger Appointed Managing Director

      July 1, 2025

    Archives

    • July 2025 (6)
    • June 2025 (807)
    • May 2025 (148)
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 incomeresearchers.com | All Rights Reserved

    Income Researchers
    • Editor’s Pick
    • Investing
    • Economy
    • Stock
    • Politics

    Read alsox

    Top 5 Canadian Mining Stocks This Week: Royalties...

    June 21, 2025

    Editor’s Picks: Gold Faces Bumpy Week on Trade...

    June 1, 2025

    Merger Discussions Between Brightstar and Aurumin

    June 30, 2025